{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:15:55Z","timestamp":1792602955483,"version":"4.5.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007300","name":"China Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007300","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.bioorg.2024.107424","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T15:23:58Z","timestamp":1714749838000},"page":"107424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Synthesis, design, and antiproliferative evaluation of 6-(N-Substituted-methyl)pyrazolo[3,4-d]pyrimidines as the potent anti-leukemia agents"],"prefix":"10.1016","volume":"148","author":[{"given":"Cheng-Yen","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin-Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Zheng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Uramaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan-Jhong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Hun","family":"Juang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fung Fuh","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2019","key":"10.1016\/j.bioorg.2024.107424_b0005","first-page":"7","article-title":"CA: Cancer","volume":"69","author":"Siegel","year":"2019","journal-title":"J. Clin."},{"key":"10.1016\/j.bioorg.2024.107424_b0010","unstructured":"G.H. Estimates, Deaths by cause, age, sex, by country and by region 2000\u20132016, (2018)."},{"key":"10.1016\/j.bioorg.2024.107424_b0015","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2991\/jegh.k.191008.001","article-title":"Current cancer epidemiology","volume":"9","author":"Mattiuzzi","year":"2019","journal-title":"J. Epidemiol. Glob. Health."},{"key":"10.1016\/j.bioorg.2024.107424_b0020","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.tcb.2005.07.004","article-title":"Cancer stem cells: lessons from leukemia","volume":"15","author":"Wang","year":"2005","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.bioorg.2024.107424_b0025","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"Vos","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2024.107424_b0030","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2024.107424_b0035","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.critrevonc.2007.04.008","article-title":"Chronic lymphocytic leukemia","volume":"64","author":"Ghia","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bioorg.2024.107424_b0040","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2024.107424_b0045","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1146\/annurev-pathol-011811-132434","article-title":"The pathogenesis of mixed-lineage Leukemia","volume":"7","author":"Muntean","year":"2012","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"10.1016\/j.bioorg.2024.107424_b0050","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1038\/onc.2016.30","article-title":"The molecular mechanics of mixed lineage leukemia","volume":"35","author":"Slany","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2024.107424_b0055","doi-asserted-by":"crossref","first-page":"6869","DOI":"10.1158\/1078-0432.CCR-06-1405","article-title":"Aurora kinases: New targets for cancer therapy","volume":"12","author":"Carvajal","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2024.107424_b0060","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/leu.2012.256","article-title":"Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target","volume":"27","author":"Hartsink-Segers","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2024.107424_b0065","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1016\/j.ejmech.2009.05.031","article-title":"El-Sayed, Synthesis of some novel pyrazolo[3,4-b]pyridine and pyrazolo[3,4-d]pyrimidine derivatives bearing 5,6-diphenyl-1,2,4-triazine moiety as potential antimicrobial agents","volume":"44","author":"Ali","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107424_b0070","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00280-009-1076-8","article-title":"SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo","volume":"65","author":"Arbitrario","year":"2010","journal-title":"Cancer Chemother, Pharmacol."},{"key":"10.1016\/j.bioorg.2024.107424_b0075","doi-asserted-by":"crossref","first-page":"86239","DOI":"10.18632\/oncotarget.13369","article-title":"Discovery of BPR1K871, a quinazoline based multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation","volume":"7","author":"Hsu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2024.107424_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13008-018-0040-6","article-title":"The functional diversity of Aurora kinases: a comprehensive review","volume":"13","author":"Willems","year":"2018","journal-title":"Cell Div"},{"key":"10.1016\/j.bioorg.2024.107424_b0085","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1021\/acs.oprd.0c00515","article-title":"Development of a robust scale-op synthetic route for BPR1K871: A clinical candidate for the treatment of acute myeloid Leukemia and solid Tumors","volume":"25","author":"Reddy","year":"2021","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.bioorg.2024.107424_b0090","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1016\/j.bmcl.2008.07.073","article-title":"Lew, Discovery of a potent and selective Aurora kinase inhibitor","volume":"18","author":"Oslob","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107424_b0095","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.bmcl.2009.01.043","article-title":"Water-soluble prodrugs of an Aurora kinase inhibitor","volume":"19","author":"Oslob","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107424_b0100","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.3390\/ijms11114326","article-title":"3D-QSAR and molecular docking studies on derivatives of MK-0457, GSK1070916 and SNS-314 as inhibitors against Aurora B kinase","volume":"11","author":"Zhang","year":"2010","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.107424_b0105","doi-asserted-by":"crossref","first-page":"86239","DOI":"10.18632\/oncotarget.13369","article-title":"Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation","volume":"7","author":"Hsu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2024.107424_b0110","doi-asserted-by":"crossref","first-page":"14477","DOI":"10.1021\/acs.jmedchem.1c01006","article-title":"Discovery of BPR1R024, an orally active and selective CSF1R inhibitor that exhibits antitumor and immunomodulatory activity in a murine colon tumor model","volume":"64","author":"Lee","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107424_b0115","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ejmech.2009.10.051","article-title":"Molecular iodine promoted synthesis of new pyrazolo[3,4-d]pyrimidine derivatives as potential antibacterial agents","volume":"45","author":"Bakavoli","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107424_b0120","doi-asserted-by":"crossref","first-page":"7166","DOI":"10.2174\/0929867325666180904125400","article-title":"Pyridine and pyrimidine derivatives as privileged Scaffolds in biologically active agents","volume":"26","author":"Chiacchio","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107424_b0125","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.bmc.2005.10.053","article-title":"Synthesis of some novel pyrazolo[3,4-d]pyrimidine derivatives as potential antimicrobial agents","volume":"14","author":"Holla","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107424_b0130","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1080\/104265090921074","article-title":"In phosphorous, sulfur and silicon","volume":"180","author":"Shamroukh","year":"2005","journal-title":"Relat. Elem."},{"key":"10.1016\/j.bioorg.2024.107424_b0135","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.bmcl.2011.01.047","article-title":"Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities","volume":"21","author":"Kumar","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107424_b0140","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejmech.2009.09.039","article-title":"Synthesis of some new pyrazolo[3,4-d]pyrimidine derivatives of expected anticancer and radioprotective activity","volume":"45","author":"Ghorab","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107424_b0145","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ejmech.2004.07.010","article-title":"Antiproliferative activity of new 1-aryl-4-amino-1H-pyrazolo[3,4-d]pyrimidine derivatives toward the human epidermoid carcinoma A431 cell line","volume":"39","author":"Schenone","year":"2004","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107424_b0150","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/(SICI)1521-4184(20004)333:4<99::AID-ARDP99>3.0.CO;2-O","article-title":"Synthesis, DNA-binding, and antiviral activity of certain pyrazolo[3,4-d]pyrimidine derivatives","volume":"333","author":"E.R. EI-Bendary, F.A. Badria","year":"2000","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2024.107424_b0155","doi-asserted-by":"crossref","first-page":"9658","DOI":"10.1016\/j.tet.2012.09.054","article-title":"One-pot synthesis and antiproliferative evaluation of pyrazolo[3,4-d]pyrimidine derivatives","volume":"68","author":"Huang","year":"2012","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bioorg.2024.107424_b0160","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2174\/1570180811666140226235350","article-title":"Synthesis and biological evaluation of new pyrazole-based thiazolyl hydrazone derivatives as potential anticancer agents","volume":"11","author":"Dilek Alt\u0131ntop","year":"2014","journal-title":"Lett. Drug Des. Discov."},{"key":"10.1016\/j.bioorg.2024.107424_b0165","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s11094-014-1130-7","article-title":"Synthesis and evaluation of thiazole\u2013pyrimidine derivatives as new anticandidal and cytotoxic agents","volume":"48","author":"Turan-Zitouni","year":"2014","journal-title":"Pharm. Chem. J."},{"key":"10.1016\/j.bioorg.2024.107424_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103470","article-title":"Overview of recent developments of pyrazole derivatives as an anticancer agent in different cell line","volume":"97","author":"Bennani","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2024.107424_b0175","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/1389557521666210325115218","article-title":"Recent progress in anticancer agents incorporating pyrazole Scaffold","volume":"22","author":"Mor","year":"2022","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107424_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113523","article-title":"Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy","volume":"221","author":"Ayati","year":"2021","journal-title":"Eur J Med Chem."},{"key":"10.1016\/j.bioorg.2024.107424_b0185","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/j.bmcl.2004.02.092","article-title":"Design, synthesis, and structure\u2013activity relationships of pyrazolo[3,4-d]pyrimidines: a novel class of potent enterovirus inhibitors","volume":"14","author":"Chern","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107424_b0190","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1016\/j.ejmech.2009.02.012","article-title":"Synthesis and anti-HSV-1 evaluation of some pyrazoles and fused pyrazolopyrimidines","volume":"44","author":"Rashad","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107424_b0195","first-page":"S10.17","article-title":"Evaluation of antioxidant properties of some pyrazolo[3,4-d]pyrimidines derivatives and their effects on mitochondria bioenergetics","author":"Rigueiroa","year":"1777","journal-title":"Biochim. Biophys Acta."},{"key":"10.1016\/j.bioorg.2024.107424_b0200","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S0968-0896(02)00562-X","article-title":"6-Dimethylamino 1H-pyrazolo[3,4-d]pyrimidine derivatives as new inhibitors of inflammatory mediators in intact cells","volume":"11","author":"Quintela","year":"2003","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107424_b0205","doi-asserted-by":"crossref","first-page":"6144","DOI":"10.1016\/j.bmcl.2009.09.016","article-title":"Optimising metabolic stability in lipophilic chemical space: The identification of a metabolically stable pyrazolopyrimidine CRF-1 receptor antagonist","volume":"19","author":"Miller","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107424_b0210","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0968-0896(96)00240-4","article-title":"1-Phenylpyrazolo[3,4-d]pyrimidines as adenosine antagonists: the effects of substituents at C4 and C6","volume":"5","author":"Chebib","year":"1997","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107424_b0215","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1016\/0960-894X(95)00420-X","article-title":"Pyrazolo[3,4-d]pyrimidines; adenosine receptor selectivity","volume":"5","author":"Chebib","year":"1995","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107424_b0220","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1081\/NCN-100107191","article-title":"Synthesis and biological activity of 4-substituted-1-[1-(2-hydroxyethoxy)-1,2,3-triazol-(4&5)-ylmethyl]-1H-pyrazolo[3,4-d] pyrimidines","volume":"20","author":"Moukha-Chafiq","year":"2001","journal-title":"Nucleos. Nucleot. Nucleic Acids."},{"key":"10.1016\/j.bioorg.2024.107424_b0225","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/jhet.343","volume":"47","author":"Su","year":"2010","journal-title":"J. Heterocyclic Chem."},{"key":"10.1016\/j.bioorg.2024.107424_b0230","doi-asserted-by":"crossref","first-page":"16157","DOI":"10.1021\/acs.joc.9b02653","article-title":"One-pot acid-promoted synthesis of 6-aminopyrazolopyrimidines from 1H-pyrazol-5-yl-N,N-dimethylformamidines or 5-amino-1H-pyrazole-4-carbaldehydes with cyanamide","volume":"84","author":"Tseng","year":"2019","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.bioorg.2024.107424_b0235","doi-asserted-by":"crossref","first-page":"47098","DOI":"10.1039\/C5RA07707A","article-title":"Vilsmeier reagent mediated synthesis of 6-[(formyloxy)methyl]-pyrazolopyrimidines via one-pot multiple tandem reaction","volume":"5","author":"Lu","year":"2015","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2024.107424_b0240","series-title":"Synthesis of \u03b2-amino carbonyl 6-(aminomethyl)- and 6-(hydroxymethyl)pyrazolopyrimidines for DPP-4 inhibition study","author":"Chung","year":"2022"},{"key":"10.1016\/j.bioorg.2024.107424_b0245","doi-asserted-by":"crossref","first-page":"10568","DOI":"10.1039\/D0CC03885G","article-title":"The development of a dedicated polymer support for the solid-phase oligosaccharide synthesis","volume":"56","author":"Panza","year":"2020","journal-title":"Commun. Chem."},{"key":"10.1016\/j.bioorg.2024.107424_b0250","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1021\/jm801563d","article-title":"Rational design, synthesis, and pharmacological properties of new 1,8-naphthyridin-2(1H)-on-3-carboxamide derivatives as highly selective cannabinoid-2 receptor agonists","volume":"52","author":"Manera","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107424_b0255","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1021\/jm00095a021","article-title":"Histamine H2-receptor agonists. synthesis, in Vitro pharmacology, and qualitative structure-activity relationships of substituted 4- and 5-(2-aminoethyl)thiazoles","volume":"35","author":"Eriks","year":"1992","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107424_b0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1541-7786.MCR-06-0208","article-title":"Roles of Aurora kinases in mitosis and tumorigenesis","volume":"5","author":"Fu","year":"2007","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bioorg.2024.107424_b0265","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3390\/chemistry3020043","article-title":"Assessment of computational tools for predicting supramolecular synthons","volume":"3","author":"Sandhu","year":"2021","journal-title":"Chemistry"},{"key":"10.1016\/j.bioorg.2024.107424_b0270","unstructured":"D.G. Allen, D.M. Coe, A.W. J. Cooper, P.M. Gore, D. House, S. Senger, S.L. Sollis, S. Vile, Wilson, C. N-pyrazolyl carboxamides as CRAC channel inhibitors. WO 2010\/122089 A l."},{"key":"10.1016\/j.bioorg.2024.107424_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.tetlet.2021.153564","article-title":"A practical method for N-cyanation of secondary amines and sulfonamides","volume":"88","author":"Hang","year":"2022","journal-title":"Tetrahedron Letts."},{"key":"10.1016\/j.bioorg.2024.107424_b0280","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.fct.2012.01.041","article-title":"Anti-inflammatory effects of ethanolic extract of Antrodia salmonea in the lipopolysaccharide-stimulated RAW246.7 macrophages and the \u03bb-carrageenan-induced paw edema model","volume":"50","author":"Huang","year":"2012","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.bioorg.2024.107424_b0285","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00204-019-02623-2","article-title":"Mitotic catastrophe and p53-dependent senescence induction in T-cell malignancies exposed to nonlethal dosage of GL-V9","volume":"94","author":"Li","year":"2020","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.bioorg.2024.107424_b0290","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2014.14","article-title":"The aurora kinases in cell cycle and leukemia","volume":"34","author":"Goldenson","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2024.107424_b0295","doi-asserted-by":"crossref","first-page":"11389","DOI":"10.1038\/ncomms11389","article-title":"Aurora A drives early signalling and vesicle dynamics during T-cell activation","volume":"7","author":"Blas-Rus","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2024.107424_b0300","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/1535-7163.MCT-08-0754","article-title":"The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model","volume":"8","author":"VanderPorten","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2024.107424_b0305","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00280-009-1076-8","article-title":"SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo","volume":"65","author":"Arbitrario","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bioorg.2024.107424_b0310","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0925-4439(02)00079-0","article-title":"Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase","volume":"1587","author":"Banerjee","year":"2002","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.bioorg.2024.107424_b0315","first-page":"3692","article-title":"DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL","volume":"111","author":"Dulucq","year":"2008","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"10.1016\/j.bioorg.2024.107424_b0320","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/carcin\/bgl235","article-title":"DHFR and MSH3 co-amplification in childhood acute lymphoblastic leukaemia, in vitro and in vivo","volume":"28","author":"Matheson","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bioorg.2024.107424_b0325","first-page":"8405","article-title":"Overexpression of dihydrofolate reductase is a factor of poor survival in acute lymphoblastic leukemia","volume":"15","author":"Organista-Nava","year":"2018","journal-title":"Oncology Lets."},{"key":"10.1016\/j.bioorg.2024.107424_b0330","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/cbdd.14328","article-title":"Design and synthesis of novel 1,2,3,4-tetrazines as new anti-leukemia cancer agents","volume":"102","author":"Eyilcim","year":"2023","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2024.107424_b0335","doi-asserted-by":"crossref","first-page":"33614","DOI":"10.1021\/acsomega.2c05206","article-title":"Design, microwave-assisted synthesis, antimicrobial and anticancer evaluation, and in silico studies of some 2-naphthamide derivatives as DHFR and VEGFR-2 Inhibitors","volume":"7","author":"Canh Pham","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2024.107424_b0340","doi-asserted-by":"crossref","first-page":"9220","DOI":"10.1021\/jm500734a","article-title":"Importance of purity evaluation and the potential of quantitative 1H NMR as a purity assay: miniperspective","volume":"57","author":"Paul","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107424_b0345","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.arabjc.2014.12.004","article-title":"Synthesis and evaluation of in vitro bioactivity for polysubstituted N-arylpyrazole derivatives","volume":"12","author":"Uramaru","year":"2019","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.bioorg.2024.107424_b0350","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.fct.2018.11.043","article-title":"Ganoderma tsugae induced ROS-independent apoptosis and cytoprotective autophagy in human chronic myeloid leukemia cells","volume":"124","author":"Hseu","year":"2019","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.bioorg.2024.107424_b0355","doi-asserted-by":"crossref","first-page":"e202100010","DOI":"10.1002\/appl.202100010","article-title":"In silico analyses of the human sperm-specific antigen 2 and its role in oral squamous cell carcinoma","volume":"1","author":"Khowal","year":"2022","journal-title":"Applied Research."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824003298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824003298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T19:15:20Z","timestamp":1717614920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824003298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":71,"alternative-id":["S0045206824003298"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107424","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis, design, and antiproliferative evaluation of 6-(N-Substituted-methyl)pyrazolo[3,4-d]pyrimidines as the potent anti-leukemia agents","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107424"}}